UY35918A - Formas cristalinas de un compuesto antiviral - Google Patents

Formas cristalinas de un compuesto antiviral

Info

Publication number
UY35918A
UY35918A UY0001035918A UY35918A UY35918A UY 35918 A UY35918 A UY 35918A UY 0001035918 A UY0001035918 A UY 0001035918A UY 35918 A UY35918 A UY 35918A UY 35918 A UY35918 A UY 35918A
Authority
UY
Uruguay
Prior art keywords
crystal forms
antiviral compound
compound
forms
dioxadiazacycloneonedecino
Prior art date
Application number
UY0001035918A
Other languages
English (en)
Spanish (es)
Inventor
Chan Johann
Bringley Dustin
Fung Peter
Keaton Katie
Lapina Olga
Morrison Henry
Pcion Dominika
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY35918A publication Critical patent/UY35918A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
UY0001035918A 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral UY35918A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
UY35918A true UY35918A (es) 2015-05-29

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035918A UY35918A (es) 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral

Country Status (12)

Country Link
US (2) US9562058B2 (enExample)
EP (1) EP3087086B1 (enExample)
JP (2) JP6568541B2 (enExample)
AR (1) AR098958A1 (enExample)
AU (1) AU2014370124A1 (enExample)
CA (1) CA2934049A1 (enExample)
ES (1) ES2708993T3 (enExample)
NZ (1) NZ720887A (enExample)
PT (1) PT3087086T (enExample)
TW (1) TW201609752A (enExample)
UY (1) UY35918A (enExample)
WO (1) WO2015100144A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201906413T4 (tr) 2013-12-23 2019-05-21 Gilead Sciences Inc Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JOP20170127A1 (ar) 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
SI2540350T1 (sl) * 2008-07-22 2015-01-30 Merck Sharp & Dohme Corp. Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
JP6568541B2 (ja) 2019-08-28
JP2019089819A (ja) 2019-06-13
JP2017503016A (ja) 2017-01-26
US20150175625A1 (en) 2015-06-25
EP3087086B1 (en) 2018-11-07
US9862728B2 (en) 2018-01-09
AR098958A1 (es) 2016-06-22
US9562058B2 (en) 2017-02-07
NZ720887A (en) 2018-01-26
AU2014370124A1 (en) 2016-06-23
US20170267694A1 (en) 2017-09-21
EP3087086A1 (en) 2016-11-02
ES2708993T3 (es) 2019-04-12
PT3087086T (pt) 2019-02-06
WO2015100144A1 (en) 2015-07-02
TW201609752A (zh) 2016-03-16
CA2934049A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
GT201700136A (es) Formas sólidas de un inhibidor ask 1
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
TWD169700S (zh) 針盤
EA201691991A1 (ru) Мультиспецифические антитела
EP3254654A4 (en) Stretch structure for absorbent article, and underpants-type disposable diaper using same
TWD170353S (zh) 項鍊
TWD166825S (zh) 飾品
EP3037852A4 (en) Wafer lens, wafer lens array, wafer lens laminate, and wafer lens array laminate
EP3537511A4 (en) ELECTRODE FOR A CELL AND CELL
EP3326413A4 (en) USER LEVELS FOR CELLULAR ARCHITECTURE OF THE FIFTH GENERATION
UY35918A (es) Formas cristalinas de un compuesto antiviral
DOP2017000288A (es) Moduladores alostéricos positivos del receptor muscarínico m2.
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
EP3279254A4 (en) Polypropylene for film condenser, biaxial stretching film for film condenser, film condenser and manufacturing methods therefor
BR112015026827A2 (pt) Formas polimórficas de cloridrato de nilotinibe
WO2014153495A3 (en) Novel stat3 inhibitors
BR112015023218A2 (pt) formas sólidas de 5- (halometil)furfural e métodos para preparar as mesmas
EP3370280A4 (en) Electrode for secondary battery comprising fine holes
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3236520A4 (en) Negative-electrode active material for electrical device, and electrical device using same
EP3067969A4 (en) Negative electrode material for secondary battery, and secondary battery using same
EP3224885A4 (en) Negative active material for secondary battery and secondary battery using the same
EP3376570A4 (en) Negative-electrode active material for electrical device, and electrical device in which said material is used

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230